NLM Gateway
A service of the U.S. National Institutes of Health
Your Entrance to
Resources from the
National Library of Medicine
    Home      Term Finder      Limits/Settings      Search Details      History      My Locker        About      Help      FAQ    
Skip Navigation Side Barintended for web crawlers only

Clinical evolution of HIV-infected patients in Bahia, Brazil, according to their serological status for HTLV-I/II infection.

Brites C, Goyanna F, Franca L, Araujo AG, Harrington W, Badars C; International Conference on AIDS.

Int Conf AIDS. 1996 Jul 7-12; 11: 323 (abstract no. Tu.B.2337).

Universidade Federal da Bahia (UFBA). Fax: (55 71) 245-7110.

Objective- To compare the clinical evolution of patients infected by the HIV-1, co-infected or not with HTLV-I/II. Methods- We reviewed the medical records of 137 HIV-1 - infected patients, followed at the UFBA's hospital, who had at least 6 months of clinical follow-up. We collected epidemiological, laboratorial and clinical data, including the frequency of opportunistic infections (OI) during the follow up period. Sera samples were tested for HTLV-I/II antibodies. The reviewers were blinded about the results of HTLV-I/II serology. Results- A total of 137 patients (81% male) were studied. Thirty patients (22%) were co-infected for: HTLV-I: 25 patients; HTLV-II: 4 patients; and, both viruses: 1 patient. The mean age (33.5 plus or minus 9.2 years) was similar, regardless gender or HTLV-I/II serology results. The mean time of follow up was 18.9 plus or minus 12.9 months. IVDU was the major risk for co-infection (p is less than 0.00001). By the time of diagnosis of HIV infection 79 (58%) patients already had AIDS. Patients co-infected by HTLV-I/II had an almost ten times higher frequency of strongyloidiasis, than those infected only by HIV-1 (p=0.029, Kruskal Wallis test), while diarrhea without an identified casual agent was more frequent among the HTLV-I/II seronegative patients (p=0.04). The levels of haemoglobin, CD4 and CD8, and absolute lymphocyte counts (ALC) were similar for both groups. Co-infected AIDS patients had higher means of CD4 (270 plus or minus 87 versus 151 plus or minus 177, p=0.03) and ALC (1540 plus or minus 770 versus 1007 plus or minus 636, p=0.01, Kruskal Wallis test). The outcome was similar regardless co-infection. Conclusion- In Bahia, Brazil, strongyloidiasis was significantly more frequent among the HIV-HTLV co-infected patients, than among those infected solely by the HIV. Also, AIDS patients harboring HTLV-I/II had a higher number of CD4+ cells and ALC. These data suggest that HIV-HTLV co-infection may modify the clinical picture of AIDS patients.

Publication Types:
  • Meeting Abstracts
Keywords:
  • Acquired Immunodeficiency Syndrome
  • Brazil
  • Communicable Diseases
  • HIV
  • HIV Infections
  • HIV Seropositivity
  • HIV Seroprevalence
  • HIV-1
  • HTLV-I Infections
  • Health Personnel
  • Human T-lymphotropic virus 1
  • Human T-lymphotropic virus 2
  • Humans
  • Lymphocyte Count
  • Male
Other ID:
  • 96922539
UI: 102218438

From Meeting Abstracts




Contact Us
U.S. National Library of Medicine |  National Institutes of Health |  Health & Human Services
Privacy |  Copyright |  Accessibility |  Freedom of Information Act |  USA.gov